NewAmsterdam Pharma NAMS
NASDAQ NAMS
$23.20 -0.96 (-3.97%)
At close: Oct 2, 2026 · 4:00 PM EDT

NewAmsterdam Pharma (NAMS) Long-Term Investments (2025 - 2026)

Updated

NewAmsterdam Pharma (NAMS) reported Long-Term Investments of $44.41 million for Q2 2026, up 0.5% from $44.17 million a year earlier but down 37.7% from the prior quarter.

Analysis

NewAmsterdam Pharma (NAMS) Long-Term Investments (2025 - 2026) Analysis & Trends

At the end of FY2025, NewAmsterdam Pharma posted Long-Term Investments of $92.61 million.

  • Five-year quarterly Long-Term Investments spans a low of $44.17 million in Q2 2025 and a high of $92.61 million in Q4 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $71.24 million (Q1 2026), $92.61 million (Q4 2025) and $53.09 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 3.86 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn -
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 266.00 Mn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn 1.22 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 69.00 Mn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 2.62 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn -
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 1.56 Bn
10 NewAmsterdam Pharma 2.84 Bn 2.84 Bn - 44.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 44.41 Mn
Mar 31, 2026 71.24 Mn
Dec 31, 2025 92.61 Mn
Sep 30, 2025 53.09 Mn
Jun 30, 2025 44.17 Mn
API Access

NewAmsterdam Pharma Long-Term Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-investments&ticker=NAMS&period=max&api_key=YOUR_API_KEY